Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTER, OPEN-LABEL, FUNCTIONALITY, RELIABILITY AND PERFORMANCE STUDY OF A SINGLE-USE AUTO-INJECTOR WITH HOME-ADMINISTERED SUBCUTANEOUS BENRALIZUMAB IN ADULT PATIENTS WITH SEVERE ASTHMA (GRECO)

Intervention/treatment:
MEDI-563 (BENRALIZUMAB)
Medical condition:
ASTHMA
Protocol code:
D3250C00031
Control number:
198455
Status:
Closed
Approved:
October 19, 2016
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02918071
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Ubaldo Martin, Global Clinical Lead Benralizumab
Organization
AstraZeneca
Phone:
+1 301 398 0163
Sponsor
ASTRAZENECA CANADA INC

Locations

Alberta

Research Site
Sherwood Park, Alberta, T8L 0N2

Ontario

Research Site
Ajax, Ontario, L1S 2J5
Research Site
Burlington, Ontario, L7N 3V2
Research Site
Kanata, Ontario, K2L 3C8
Research Site
Mississauga, Ontario, L5A 3V4

Quebec

Research Site
Montreal, Quebec, H3G 1L5
Research Site
Montreal, Quebec, H4J 1C5
Research Site
Québec, Quebec, G1G 3Y8
Research Site
Québec, Quebec, G1V 4W2
Research Site
Sherbrooke, Quebec, J1H 5N4
Research Site
Trois-Rivières, Quebec, G8T 7A1

Results

See the results from the trial NCT02918071. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?